Anti-COVID drug created by artificial intelligence has entered phase I clinical trials

Biotech startup Insilico Medicine has announced the start of a phase I clinical trial of an artificial intelligence-driven COVID-19 drug. The company claims that the drug is effective against all variants of the virus.

Here's What We Know

The drug ISM3312, created with the help of artificial intelligence, may become an alternative to Paxlovid and solve its shortcomings. These include unpleasant side effects and drug resistance due to the persistent COVID mutation.

According to Insilico, the drug identified using the PandaOmics AI platform effectively targets the most important proteins of the coronavirus. The company's experts also used the Chemistry42 generative chemistry platform to create new molecules to inhibit this protein.

Preclinical studies have revealed ISM3312's potential to reduce viral load in lung tissue and reduce lung inflammation. Results from phase I clinical trials are expected by the end of 2023.

Source: Fox News